TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/23/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA
6. BABA
7. AVGO
8. SPCX
9. NTES
10. DE

Go back to TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
(NASDAQ: RNAZ) Delayed: 2.87 -0.1 (3.37%)
Previous Close $2.97    52 Week High $ 
Open $2.90    52 Week Low $ 
Day High $3.00    P/E N/A 
Day Low $2.87    EPS $ 
Volume 42,159